Literature DB >> 981398

Xanthelasma: follow-up on results after surgical excision.

B C Mendelson, J K Masson.   

Abstract

Xanthelasma palpebrarum is the most common xanthoma and is associated with other xanthomas or hyperlipemia syndromes in only 5 percent of the patients--even though one third of the affected patients have an elevated serum cholesterol level. Surgical excision is simple, safe, leaves minimal scarring, and will be definitive in more than half of the patients being treated for the first time. Reexcision may still be worthwhile if the xanthelasma recurs. However, recurrence is to be anticipated if all 4 eyelids are involved, if there is an underlying hyperlipemia syndrome, or if there has been more than one previous recurrence.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 981398

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  5 in total

1.  Inflammatory Mediators in Xanthelasma Palpebrarum: Histopathologic and Immunohistochemical Study.

Authors:  Maria S Govorkova; Tatyana Milman; Gui-Shuang Ying; Wei Pan; Rona Z Silkiss
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2018 May/Jun       Impact factor: 1.746

2.  Treatment of xanthelasma palpebrarum with argon laser photocoagulation. Argon laser and xanthelasma palpebrarum.

Authors:  Emel Basar; Halit Oguz; Hakan Ozdemir; Sehirbay Ozkan; Hasim Uslu
Journal:  Int Ophthalmol       Date:  2004-01       Impact factor: 2.031

3.  Outcomes of surgical management of xanthelasma palpebrarum.

Authors:  Hoon Young Lee; Ung Sik Jin; Kyung Won Minn; Young-Oh Park
Journal:  Arch Plast Surg       Date:  2013-07-17

Review 4.  Xanthelasma palpebrarum - a brief review.

Authors:  Pragya A Nair; Rochit Singhal
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-12-18

Review 5.  Xanthelasma: An Update on Treatment Modalities.

Authors:  Zainab Laftah; Firas Al-Niaimi
Journal:  J Cutan Aesthet Surg       Date:  2018 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.